PEPTILOGICS INC

• TRUSTEES OF BOSTON UNIVERSITY

  UEI THL6A6JLE1S7

  $1.5M

  Subcontractor to this prime · 1 sub-award · latest Dec 6, 2024

  • Office of Assistant Secretary for Preparedness and Response
  • “PEPTILOGICS IS A BIOTECHNOLOGY COMPANY THAT UTILIZES AN INNOVATIVE PLATFORM TO DEVELOP NOVEL PEPTIDE THERAPEUTICS TO ADDRESS UNMET MEDICAL NEEDS. OUR PIPELINE INCLUDES A NOVEL CLASS OF ENGINEERED CATIONIC ANTIBIOTIC PEPTIDES. OUR LEAD CANDIDATE, PLG0206, BASED ON NATURALLY OCCURRING ANTIMICROBIAL PEPTIDES, EXHIBITS BROAD-SPECTRUM ACTIVITY AGAINST CLINICALLY IMPORTANT MDR GRAM-POSITIVE (S. AUREUS, INCLUDING MRSA, AND E. FAECIUM, INCLUDING VRE) AND GRAM-NEGATIVE (P. AERUGINOSA, E. COLI, AND A. BAUMANNII) PATHOGENS. PLG0206 EXHIBITS THE ABILITY TO RAPIDLY INACTIVATE BOTH PLANKTONIC AND BIOFILM PATHOGENS. THIS WITH ITS BROAD-SPECTRUM ACTIVITY MAKE IT AN IDEAL DEVELOPMENT CANDIDATE FOR PREVENTING INVASIVE INFECTIONS. PLG0206 TARGETS AND DISRUPTS THE BACTERIAL MEMBRANE, CAUSING RAPID BACTERIAL DEATH VIA CELLULAR CHEMICAL IMBALANCE. SINCE BACTERIAL MEMBRANES ARE A CONSERVED EVOLUTIONARY TARGET, THIS MOA APPEARS TO LIMIT THE RISK FOR RESISTANCE COMPARED TO OTHER ANTIBIOTICS. WITH RAPID BACTERICIDAL AND ANTI-BIOFILM ACTIVITY ON CONTACT, PLG0206 IS BEING DEVELOPED FOR THE PREVENTION OF TRAUMATIC FRACTURE-RELATED INFECTIONS (FRI) VIA LOCAL ADMINISTRATION IN CONJUNCTION STANDARD SURGICAL CARE. FRI IS A SERIOUS, LIFE-THREATENING INFECTION WITH SIGNIFICANT ECONOMIC BURDEN. FRI TREATMENT REQUIRES HOSPITALIZATION AND ONE OR MORE REPEAT SURGICAL PROCEDURES. MICROORGANISMS THAT CAUSE FRI INCLUDE S. AUREUS, COAGULATE-NEGATIVE STAPHYLOCOCCUS SPP., ENTEROCOCCUS SPP., AND AEROBIC GRAM-NEGATIVE BACILLI. THE POTENTIAL INFECTING PATHOGEN IS UNKNOWN AT THE TIME OF TRAUMATIC INSULT AND INITIAL SURGERY. CLINICAL PRACTICE GUIDELINES RECOMMEND 2-5 DAYS OF SYSTEMIC ANTIBIOTICS FOLLOWING TRAUMATIC INJURY TO PREVENT FRI. DESPITE THIS, TRAUMATIC FRACTURES HAVE A HIGH INFECTION RATE (UP TO 40%). FRI OFTEN REQUIRES MULTIPLE SURGICAL PROCEDURES, LEADING TO SUBSTANTIAL MORBIDITY AND MORTALITY WITH AN UP TO 25% 5-YEAR MORTALITY RISK. CURRENT STRATEGIES DO NOT ADEQUATELY PREVENT THE INFECTIONS THAT LEAD T”

No reported sub-awards as a prime contractor.

No active exclusion on record (checked Nov 14, 2026).

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

No confirmed match on the Consolidated Screening List (screened Nov 14, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.